Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. by Kondo, A. et al.
British Journal of Cancer (1996) 73, 1166-1170
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal
carcinomatosis in mice
A Kondo, M Maeta, A Oka, S Tsujitani, M Ikeguchi and N Kaibara
First Department ofSurgery, Faculty ofMedicine, Tottori University, 36-1 Nishimachi, Yonago 683, Japan.
Summary The intraperitoneal (i.p.) administration of cisplatin (CDDP) is one of the most effective therapies
for cancers that are confined to the abdominal cavity. However, the effect offluid osmolarity on the therapeutic
efficacy of i.p. administration of CDDP has not been well established. In the current study, hypotonic (154
mosmol 1-l), isotonic (308 mosmol 1-l) and hypertonic (616 mosmol 1-l) solutions of CDDP were prepared
for an evaluation of their therapeutic efficacy in an experimental system. After i.p. administration, uptake of
CDDP in vivo by tumour cells in hypotonic solution was significantly greater than in isotonic or hypertonic
solution. The 50% lethal dose (LD50) value of CDDP in hypotonic solution (12.1 mg kg-') was lower than
that in isotonic solution (16.9 mg kg-') and than that in hypertonic solution (28.6 mg kg-1). However, when a
dose equal to one-half of the LD50 was administered in each solution to mice with i.p. tumours, survival of
mice given the CDDP in hypotonic solution was significantly prolonged as compared with the survival of the
other mice. These results demonstrate that the therapeutic efficacy ofi.p. CDDP in mice is augmented when the
drug is administered in hypotonic solution.
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Intraperitoneal (i.p.) chemotherapy has been used for
adjuvant post-surgical or palliative treatment of ovarian
and gastrointestinal malignancies (Cunliffe and Sugarbaker,
1989; Los and McVie, 1990). The peritoneal cavity is a
common site of tumour recurrence after initial 'radical'
surgical treatment. Intraperitoneal dissemination of cancer is
often widespread but it tends to be confined to the peritoneal
cavity. For this reason, i.p. chemotherapy is anatomically
appropriate for malignancies within the peritoneal cavity.
The major attraction of i.p. chemotherapy is that the
peritoneal cavity can be exposed to higher concentrations
of the drug than the rest of the body, and the accumulation
of the drug in peritoneal tumours is higher than can be easily
achieved by i.v. administration (Los et al., 1989).
Cisplatin (CDDP) is one of the most useful drugs for i.p.
chemotherapy (Tsujitani et al., 1993), but CDDP penetrates
to a distance of only 1-3 mm beneath the surface of
peritoneal tumour nodules, in spite of its high ability to
penetrate tumours (Los and McVie, 1990). Thus, the
therapeutic effect of this drug is confined exclusively to
microscopic or small-volume residual tumours. (Los &
McVie, 1990; Markman et al., 1993).
The increased accumulation in tumour cells and the
enhanced cytotoxicity of CDDP in hypotonic solution have
been confirmed in vitro (Smith and Brock, 1989; Groose et
al., 1986). However, the effects of fluid osmolarity on the
accumulation and cytotoxicity have not yet been examined
under i.p. conditions, and the effects of osmolarity on the
therapeutic efficacy of i.p. CDDP remains to be established.
In the current study, we attempted to clarify the effect of
fluid osmolarity on i.p. CDDP chemotherapy. We compared
the uptake of CDDP by tumour cells, acute toxicity in mice
and rats, and the therapeutic effect of CDDP in tumour-
bearing mice between solutions of CDDP with different
osmolarities.
Materials and methods
Animals
Male ddy mice (6 weeks old, 30 g) and male Donryu rats (8
weeks old, 200-250 g) were obtained from Shimizu
Laboratory Animal Center (Kyoto, Japan). The animals
were housed in plastic cages and were allowed free access to
food pellets and tap water.
Tumour cells
Ehrlich ascites tumour (EAT) cells were maintained by
weekly i.p. passage in male ddy mice and were obtained by
paracentesis.
Drug
CDDP was supplied by Nippon Kayaku (Tokyo, Japan) as
Landa inj, 0.5 mg ml-' CDDP solution in 0.9% sodium
chloride.
Solutions
Three solutions of 154, 308 and 616 mosmol 1-l, were
prepared. The solution of CDDP from the supplier was
diluted in sterilised distilled water plus sodium chloride and
solutions containing 0.45% (hypotonic), 0.9% (isotonic) and
1.8% (hypertonic) sodium chloride were prepared. The
osmolarities of these solutions were determined by freezing-
point depression with an automatic osmometer (ONE-TEN
osmometer; Fiske Associates, Needham Heights, MA, USA)
and ranged between 153 and 159 mosmol 1-', 305 and 311
mosmol I` and 613 and 620 mosmol 1-' , respectively. These
solutions were prepared immediately before experiments.
Intracellular accumulation of CDDP in vivo
Six-week-old male ddy mice were given an i.p. injection of
2 x 106 EAT cells. Four days later, CDDP (5 mg kg-') was
administered i.p. in each solution of sodium chloride at
0.1 ml g` body weight. After 30 or 60 min, mice were
sacrificed by cervical dislocation, the belly was opened, and
5 ml of ice-cold 0.9% sodium chloride was flushed into the
peritoneal cavity. Fluid containing cells was withdrawn and
Correspondence: A Kondo
Received 10 July 1995; revised 3 November 1995; accepted 21
December 1995Intraperitoneal hypotonic CDDP chemotherapy
A Kondo et al 0
1167
the cells were washed twice. The cells were stored at - 70°C
for determinations of cellular platinum content.
Evaluation of toxicity against mice and rats
Six tumour-free ddy mice per group were given an i.p.
injection of various doses of CDDP in each solution of
sodium chloride. The volume of solution administered was
0.1 ml g-' body weight. The mice were observed for 14 days
after administration of CDDP and the day of death was
recorded. The 50% lethal dose (LD50) was calculated for
CDDP in each solution of sodium chloride by the graphic
approximation method of Finney (1952).
The pharmacokinetics and toxicity of CDDP were
analysed in tumour-free Donryu rats. Rats were given an
i.p. injection of CDDP (3 mg kg-') in each solution of
sodium chloride. The volume of solution was 100 ml kg-'
body weight (CDDP, 30 ,ug ml-'). Six rats per group were
sacrificed 5, 15, 30, 60, 180 and 480 min after the i.p.
injection of CDDP, for collection of plasma and peritoneal
fluid and determinations of levels of both free and protein-
bound platinum. Some of each sample of plasma and
peritoneal fluid was passed through an ultrafiltration
membrane (Centrifree MPS-3, Amicon, Beverly, MA, USA)
with centrifugation 1500 g for separation of free platinum
from total platinum (Whitlam and Brown, 1981). Body
weight and plasma levels of blood urea nitrogen (BUN) and
creatinine were examained 3 and 5 days after injection of
CDDP using another six rats from each group.
Study of therapeutic efficacy
Six-week-old male ddy mice were inoculated i.p. with EAT
cells (2 x 106). Twenty-four hours and 4 days after inocula-
tion, CDDP (5 mg kg-') in each of the three solutions of
sodium chloride was administered i.p. in a volume of
0.1 ml g-' body weight to mice in three groups (ten mice
per group). In addition, 4 days after inoculation, CDDP (at
half of LD50) in each of the three solutions of sodium
chloride was administered in the same manner to three
further groups (ten mice per group). In the latter experiment,
the dose of CDDP (half of LD_O) did not affect the survival
of tumour-free mice. All mice were monitored until death or
for 60 days to determine survival time.
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Analysis ofplatinum
The intracellular accumulation ofplatinum was analysed by a
modified version of the method of LeRoy et al. (1977). In
brief, cell pellets were digested by heating with 60% nitric
acid and then the mixture was evaporated to dryness. Each
sample was dissolved in 0.1 N nitric acid and platinum was
quantitated by flameless atomic absorption spectrophotome-
try (polarised Zeeman atomic absorption spectrophotometer
180-80; Hitachi, Tokyo, Japan). The intracellular accumula-
tion of platinum was normalised with respect to the cellular
protein content, which was determined by the method of
Lowry et al. (1951).
For the determination of total and free platinum in the
plasma and peritoneal fluid, each sample was dissolved in
0.1 N nitric acid and platinum was quantitated in the same
manner as described above.
Statistics
Intracellular accumulations of platinum were compared by
Student's t-test. Differences in survival times were tested for
significance by the log-rank test.
Results
Accumulation ofi.p. administered CDDP by EAT cells in mice
The accumulation of platinum by EAT cells was inversely
correlated with the osmolarity of the three solutions in which
CDDP was dissolved (Figure 1). The differences were
significant at all time points between CDDP in hypotonic
and CDDP in isotonic solution and between CDDP in
isotonic and CDDP in hypertonic solutions (P<0.01). The
amount of cellular platinum taken up in hypotonic solution
was 2.6-3.3 times higher than that taken up in isotonic
solution, and it was 10.9-14.8 times higher than that taken
up in hypertonic solution.
Acute toxicity against mice and rats
The LD50 values of CDDP in each solution of sodium
chloride after i.p. administration are shown in Table I. The
toxicity of CDDP was increased 1.4-fold greater in hypotonic
solution than in isotonic solution, and it was 2.4-fold greater
than that in hypertonic solution. These results indicate that
the acute toxicity of CDDP was inversely correlated with the
osmolarity of the solution.
Tables II and III show pharmacokinetics of platinum in
plasma and peritoneal fluid in rats after i.p. injection of
CDDP in each solution of sodium chloride respectively. We
were able to collect peritoneal fluid for 3 h when CDDP was
administered in hypotonic solution. However, collection was
no longer possible after 8 h because of the complete
disappearance of fluid from the peritoneal cavity. We were
able to collect fluid for up to 8 h after CDDP had been
injected in isotonic or hypertonic solution. Plasma levels of
both total and free platinum were maximal (Cmax) after
30 min in hypotonic and isotonic solution, with significantly
higher levels in the case of hypotonic solution than in that of
isotonic or hypertonic solution. Levels of both total and free
platinum in peritoneal fluid indicated the more rapid
disappearance of i.p. CDDP in hypotonic solution and the
-
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Figure 1 Effects of osmolarity of the solution on the uptake of
i.p. cisplatin by i.p. EAT cells. Cisplatin was administered i.p. in
hypotonic, isotonic or hypertonic solution, as described in
Materials and methods. At the times indicated (dwell times),
mice were sacrificed, cell-containing fluid was withdrawn and
intracellular platinum (Pt) was quantitated as described in the
text. _, Hypotonic; =L, isotonic; g, hypertonic.
Table I Acute toxicity of CDDP
LD50 valuea
Osmolarity ofsolution ofCDDP (mg kg-' ofbody weight)
Hypotonic 12.1 (11.2-13.I)b
Isotonic 16.9 (15.7- 18.3)
Hypertonic 28.6 (27.2-30.1)
a50% lethal dose. b95% confidence interval.
lb^^
F/, m04 Intraperitoneal hypotonic CDDP chemotherapy
A Kondo et al
slower disappearance in hypertonic solution. BUN, creatinine
and body weight determinations were performed after 3 and
5 days. These changes were greater on day 5 (the time of
maximally observed toxicity; Kociba and Sleight, 1971) than
on day 3. Plasma levels of BUN and creatinine in the case of
the hypotonic solution were significantly higher than those in
the case of the isotonic or hypertonic solution, as shown in
Table IV. The increase in body weight was minimum in the
case of hypotonic solution, suggesting augmented anorexia,
nausea, vomiting and evidence of another toxicity.
Study of therapeutic efficacy
The therapeutic efficacy of a given dose of CDDP
(5 mg kg-') in each solution of sodium chloride is shown
in Figures 2a and b. Survival was significantly prolonged
when CDDP was administered i.p. in hypotonic solution, as
compared with that in isotonic or hypertonic solution. At
doses of CDDP equal to half of the LD50 in each solution,
survival was significantly prolonged when CDDP was
administered i.p. in hypotonic solution, as compared with
that in isotonic or hypertonic solution, in spite of the low
dose of CDDP used (Table V).
Discussion
Accumulation of CDDP
Smith and Brock (1989) showed that a reduction in
osmolarity from 300 to 240 mosmol 1-l caused a 3-fold
increase in the uptake of CDDP by Chinese hamster ovary
cells in vitro. Groose et al. (1986) measured the colony-
forming ability of human transitional carcinoma cells, and
showed that a reduction in osmolarity from 290 to 200
mosmol l` increased the clonogenic cell killing by CDDP at
2.5 Mg ml-' from 20% to 99%. However, the increased
accumulation of the drug in tumour cells and the enhanced
cytotoxicity of CDDP in hypotonic solution have not been
previously demonstrated in vivo. In the current study,
increased uptake of CDDP by tumour cells under hypotonic
conditions was confirmed under i.p. conditions. Stephen et al.
(1990) observed the swelling of cells in hypotonic solution
and the shrinking of cells in hypertonic solution. The
different rates of uptake of CDDP might be related to the
movement of water between cells and the surrounding
solution. As water flows into cells, the dissolved drug is
carried with it into the cells.
The cytotoxicity of CDDP involves binding to DNA as
the cytotoxic target, as well as the accumulation of the drug
in tumour cells (Bungo et al., 1990; Los et al., 1991; Eastman,
1987; Kraker and Moore, 1988). Hypotonic solutions have
been known to cause the expansion of chromatin (Brasch et
al., 1972) and Chiu et al. (1986) indicated that, when Chinese
hamster V79 cells were irradiated under hypotonic condi-
tions, formation of DNA-protein cross-links (DPC) was
enhanced. They suggested that diffusion of radiation-
generated free radicals to the expanded chromatin caused
increased formation of free radicals on the DNA. The
increased rate of formation of DPC would then result from
increased rates of covalent reactions between radicals on
DNA and proteins.
Acute toxicity
Litterst (1981) found that the LDso values of CDDP, when
the drug was administered i.p. to mice in 0.9% sodium
Table II Pharmacokinetic data on total (protein-bound and -unbound) and free (protein-unbound) platinum in plasma after i.p. injection of
CDDP (3 mg kg-1) in each solution in rats
Plasma concentration ofplatinum (ug ml-'; mean ±s.d.)a
CDDP vehicle 5 min 15 min 30 min 60 min 180 min
Total platinum Hypotonic 0.60+0.05 1.08+0.18 1.55±0.15b 0.91+0.12d 0.46+ 0.06
Isotonic 0.37 + 0.04 0.65+0.08 0.92 ±0.07c 0.81 + O.Olb 0.45+0.05
Hypertonic 0.44±0.06 0.80 ±0.09 0.78 +0.07c 0.60± 0.08c 0.40 ±0.04
Free platinum Hypotonic 0.37+0.05 0.81 +0.08 1.00+0.job 0.59 0.job 0.04+O.Ole
Isotonic 0.27+0.02 0.48+0.07 0.63 +0.07c 0.50io09b 0.12± 0.03f
Hypertonic 0.39 +0.04 0.60+ 0.12 0.59 ±0.08c 0.36 0 0.05c 0.14±0.01g
aUnderlines indicate maximal plasma concentration ofplatinum(Cmax). bSignificant (P<0.001) increase vsc.dSignificant (P<0.01) increase vsc.
cSignificant (P<0.001) decrease vs g. eSignificant (P<0.001) decrease vs f.
Table III Pharmacokinetic data on total (protein-bound and -unbound) and free (protein-unbound) platinum in peritoneal fluid after i.p.
injection of CDDP (3 mg kg-') in each solution in rats
Peritonealfluid concentration ofplatinum(Mg mrl; mean ±s.d.)
CDDP vehicle 5 min 15 min 30 min 60 min 180 min
Total platinum Hypotonic 19.90+0.24 19.48+1.53 11.34+ 1.31 6.90+0.53 0.51 ±0.06a
Isotonic 19.24+ 1.44 17.14+0.29 13.52±0.54 8.41 +0.34 2.33+0.46b
Hypertonic 18.43+ 1.54 16.21 +0.38 14.17+0.56 8.46+0.53 2.84+0.35b
Free platinum Hypotonic 19.04+0.78 18.34+ 1.28 10.60+ 1.57 5.81 +0.58a 0.46+0.85a
Isotonic 18.33 + 1.38 16.14+0.48 12.24+0.59 7.49+ 3.28 1.54+0.66b
Hypertonic 17.74+ 1.13 15.43+0.33 12.41 +0.84 7.94+ 0.57b 1.84+0.09b
aSignificant (P<0.001) decrease vs b.
Table IV Toxicity in rats 5 days after i.p. injection of CDDP (3 mg kg-') in each solution of sodium chloride
(mean+s.d.)
Osmolarity ofsolution ofCDDP BUN (mg dlh)a Creatinine (mg dl1) Body weight ratio (%)b
Hypotonic 41.2+16.0c 1.00+0.38e + 1.17±8.219
Isotonic 17.0 2.6- 0.48 ± 0.07f +9.72+ 1.77
Hypertonic 14.4+0.88d 0.46+0.17i + 10.6+0.17h
aBlood urea nitrogen. bBody weight ratio = [(post treatment)-(pre treatment)]/(pre treatment)] x 100. 'Significant
(P<0.01) increase vs d. eSignificant (P<0.05) increase vs f. gSignificant (P<0.05) decrease vs h.chloride, distilled water (DW) and 4.5% sodium chloride
were 15.3, 10.8 and 24.5 mg kg-' respectively. In our series
the concentrations of sodium chloride in the solution wer
0.45%, 0.9% and 1.8%, so conditions were mild as compare(
with those in Litterst's study. However, the increased toxicit
of CDDP in hypotonic solution and its decreased toxicity ii
hypertonic solution were confirmed. The reason for th
difference in toxicity that follows a change in osmolarity i
difficult to establish. One possible reason is that a chemica
change occurs in the CDDP molecule. CDDP is easil
hydrated at a low concentration of chloride ions, as is foun
in intracellular fluid or when the concentration of sodiun
chloride is low (Rosenberg, 1979; Daley-Yates and McBrien
1984). Another reason for the difference in toxicity might b
derived from a difference in the concentration of CDDP i]
the bloodstream. The development of nephrotoxicity i
correlated with elevated plasma levels of platinum (Camp
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Figure 2 Therapeutic effects of CDDP (5mg kg -) on peritoneal
carcinomatosis in mice. , hypotonic solution;-
isotonic solution;-
- -, hypertonic solution;- - - -, control (no
treatment). (a) i.p. treatment administered 24h after inoculation
of tumour cells. P<0.001 (A vs C, D), P<0.005 (C vs D),
P<0.05 (B vs C). (B) i.p. treatment administered 4 days after
inoculation of tumour cells. P<0.005 (A vs D), P<0.05 (A vs B,
C; B vs D).
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bell et al., 1983). Our pharmacological experiments with rats
indicated both the more rapid disappearance of i.p. CDDP
and higher plasma levels of platinum after administration of
CDDP in hypotonic solution, as well as the slower
disappearance and lower plasma levels of platinum in the
case of hypertonic solution.
Therapeutic effects
Iy There are, to our knowledge, no previous reports of the
d effectiveness of CDDP in hypotonic solution in peritoneal
n carcinomatosis. In some preliminary studies, hypotonic
n, solution increased the toxicity of CDDP when almost the
e same effective dose of the drug was used, and high levels of
n sodium chloride in solution decreased the toxicity of CDDP
is without reducing its anti-tumour effect when the drug was
administered i.p. (Litterst, 1981; Aamdal et al., 1984;
Mannel et al., 1989). These earlier results conflict with
ours. In these earlier experiments, the volume used for an
i.p. injection of 0.01 ml g-1 was 10- 5% of the volume
that we used. To obtain a uniform distribution of instilled
material within the abdomen, a large volume of solution is
essential (Cunliffe and Sugarbaker, 1989). If drugs are
instilled in small volumes of fluid, the distribution of the
drug may be inadequate and some of the tumour cells
might not even come into contact with the drug.
Furthermore, when CDDP is prepared in solutions that
are administered in a small volume and at low osmolarity,
the i.p. administered drug might soon disappear and not
make adequate contact with tumour cells. Such disappear-
ance and inadequate contact might explain the earlier
preliminary reports that i.p. CDDP in hypotonic solutions
was more toxic and less effective. In our experiments, mice
that received 0.1 ml of solution g-' body weight showed
considerable abdominal distension. In spite of its more
rapid disappearance from the peritoneal cavity, i.p.
administered CDDP in hypotonic solution might make
adequate contact with tumour cells and might be able to
exert a sufficient cytotoxic effect. By contrast, i.p. CDDP in
hypertonic solution might remain longer in the i.p. cavity
and make better contact with tumour cells, but uptake into
cells might be decreased and so the drug might be less
cytotoxic in spite of its injection at a high dose.
In this study, we found that a low i.p. dose of CDDP in
hypotonic solution was more effective for treatment of mice
with i.p. EAT cells than a higher dose ofCDDP in isotonic or
hypertonic solution, and we confirmed the increased cellular
accumulation of CDDP in hypotonic solution. These data
indicate that i.p. chemotherapy with CDDP in hypotonic
solution might be a promising modality for the treatment of
the incipient phase of peritoneal carcinomatosis without
macroscopic major peritoneal solid tumours. It might also
be useful for prophylaxis of post-operative peritoneal
recurrence in patients with advanced gastric or ovarian
cancer, without macroscopic peritoneal metastasis, when
used immediately after surgery and before closure of the
peritoneal cavity. As we used EAT cells, which behave like
tumour cells in suspension, our results may not be applicable
to peritoneal carcinomatosis with multiple solid tumours.
Further analysis of an increased penetration by CDDP of i.p.
tumour nodules as a consequence of hypotonicity requires
studies in other tumour systems.
Table V Therapeutic effects of CDDP (at half of each LD50) on peritoneal carcinomatosis in mice
Osmolarity ofsolution ofCDDP Dose of CDDP (mg kg-') MST±s.d.a Survivors b
Hypotonic 6.0 mg kg-' 43.1 ± 10.6c 3/10
Isotonic 8.5 mg kg 27.9±5.5d 1/10
Hypertonic 14.5 mg kg-' 28.2 5.5d 0/10
Control - 16.8+1.8e 0/10
aMean survival time. bNumber of mice surviving for 60 days. cSignificant (P<0.05) increase vs d. dSignificant (P<0.01)
increase vs e.Intraperitoneal hypotonic CDDP chemotherapy
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